Treatment with cisplatin alone causes side effects that increase the CSC-like properties of gastric cancer cells by activating the interleukin-6 (IL-6)-mediated signal transducer and activator of transcription 3 (Stat3) signaling; however, cotreatment with SFN improves the chemotherapy efficacy. This evidence concerns the gene IL6 and gastric cancer.